Results 31 to 40 of about 2,263,596 (244)

Characterization and in vitro data of antibody drug conjugates (ADCs) derived from heterotrifunctional linker designed for the site-specific preparation of dual ADCs

Data in Brief, 2018
Experimental procedures and 1H and 13C NMR of the heterotrifunctional linker used for preparation of dual drug conjugates and PBD payload are included.
Amit Kumar, Krista Kinneer, Luke Masterson, Ebele Ezeadi, Philip Howard, Herren Wu, Changshou Gao, Nazzareno Dimasi   +7 more
doaj   +1 more source

Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer. [PDF]

PLoS ONE, 2016
Antibodies are widely available and cost-effective research tools in life science, and antibody conjugates are now extensively used for targeted therapy, immunohistochemical staining, or in vivo diagnostic imaging of cancer.
Steve Knutson, Erum Raja, Ryan Bomgarden, Marie Nlend, Aoshuang Chen, Ramaswamy Kalyanasundaram, Surbhi Desai   +6 more
doaj   +1 more source

Antibody-drug conjugates for cancer therapy [PDF]

Farmacja Polska, 2021
Antibody – drug conjugates (ADCs) are drugs designed to target specific anti-cancer treatment. ADCs are immunoconjugates comprised of a monoclonal antibody attached to cytotoxic drug via a chemical linker.
Anna Grzywa
doaj   +1 more source

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug conjugates (ADcs) [PDF]

, 2020
Antibody-Drug Conjugates (ADCs) developed as a targeted treatment approach to deliver toxins directly to cancer cells are one of the fastest growing classes of oncology therapeutics, with eight ADCs and two immunotoxins approved for clinical use. However,
Sachouli, E., Cheung, A., Thurston, D.E., Figini, M., Tutt, A.J.N., Spicer, J.F., Marlow, R., Zlatareva, I., Karagiannis, S.N., Morad, H., Crescioli, S., Bucaite, G., Lacy, K.E., Hoffmann, R.M., McDonnell, J.M., Mele, S., Larcombe-Young, D.   +16 more
core   +1 more source

An Immunosuppressive Antibody–Drug Conjugate [PDF]

Journal of the American Chemical Society, 2015
We have developed a novel antibody-drug conjugate (ADC) that can selectively deliver the Lck inhibitor dasatinib to human T lymphocytes. This ADC is based on a humanized antibody that selectively binds with high affinity to CXCR4, an antigen that is selectively expressed on hematopoietic cells.
Wang, Rongsheng E, Liu, Tao, Wang, Ying, Cao, Yu, Du, Jintang, Luo, Xiaozhou, Deshmukh, Vishal, Kim, Chan Hyuk, Lawson, Brian R, Tremblay, Matthew S, Young, Travis S, Kazane, Stephanie A, Wang, Feng, Schultz, Peter G   +13 more
openaire   +4 more sources

Improved translation of stability for conjugated antibodies using an in vitro whole blood assay

mAbs, 2020
For antibody-drug conjugates to be efficacious and safe, they must be stable in circulation to carry the payload to the site of the targeted cell. Several components of a drug-conjugated antibody are known to influence stability: 1) the site of drug ...
Aimee Fourie-O’Donohue, Phillip Y. Chu, Josefa dela Cruz Chuh, Robert Tchelepi, Siao Ping Tsai, John C. Tran, William S. Sawyer, Dian Su, Carl Ng, Keyang Xu, Shang-Fan Yu, Thomas H. Pillow, Jack Sadowsky, Peter S. Dragovich, Yichin Liu, Katherine R. Kozak   +15 more
doaj   +1 more source

AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production [PDF]

, 2023
The site-directed chemical conjugation of antibodies remains an area of great interest and active efforts within the antibody-drug conjugate (ADC) community.
Muneki, Isokawa, Sayaka, Kawaguchi, Tatsuya, Okuzumi, Yuri, Ooba, Rika, Takasugi, Yutaka, Matsuda, Natsuki, Shikida, Kazutaka, Shimbo, Tomohiro, Fujii, Tomohiro, Watanabe, Akira, Nakayama, Kei, Yamada, Takuya, Seki, Yusuke, Iwai, Noriko, Hatada, Brian. A., Mendelsohn, Kazutoshi, Takahashi   +16 more
core   +2 more sources

Monodisperse Polysarcosine-based Highly-loaded Antibody-Drug Conjugates [PDF]

, 2018
We report the synthesis of monodisperse (i.e. discrete) polysarcosine compounds and their use as a hydrophobicity masking entity for the construction of highly-loaded homogeneous β- glucuronidase-responsive antibody-drug conjugates (ADCs).
Warren, Viricel, Guy, Fournet, Sabine, Beaumel, Benoît, Joseph, Sébastien, Papot, Emeline, Perrial, Charles, Dumontet   +6 more
core   +2 more sources

A RAGE-Targeted Antibody-Drug Conjugate: Surface Plasmon Resonance as a Platform for Accelerating Effective ADC Design and Development

Antibodies, 2019
Antibodies, antibody-like molecules, and therapeutics incorporating antibodies as a targeting moiety, such as antibody-drug conjugates, offer significant potential for the development of highly efficacious drugs against a wide range of disorders. Despite
Gareth D. Healey, Asa Frostell, Tim Fagge, Deyarina Gonzalez, R. Steven Conlan   +4 more
doaj   +1 more source

Antibody–Biopolymer Conjugates in Oncology: A Review

Molecules, 2023
Cancer is one of the most prevalent diseases and affects a large proportion of the population worldwide. Conventional treatments in the management include chemotherapy, radiotherapy, and surgery.
Vivek P. Chavda, Pankti C. Balar, Divya Teli, Majid Davidson, Joanna Bojarska, Vasso Apostolopoulos   +5 more
doaj   +1 more source